Medicaid's Coverage Reversal, a $10B Bet in Biotech & The Next Digital Health Giant

Healthcare is entering its next phase of normalization. Medicaid coverage is declining, strategic biotech M&A is accelerating, and new investment themes continue to emerge. This week, we unpack what matters—and ask which digital health category is most likely to create the next $10B company.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

HEADLINE OF THE WEEK

Medicaid Redeterminations Are Reversing Coverage Gains

The post-pandemic coverage unwind is showing up clearly in the data. Between 2023 and 2024, Medicaid coverage fell by 1.0 percentage point among people ages 0-64 and by 1.5 percentage points among children, while the uninsured rate increased across every demographic group. Meanwhile, enrollment in employer-sponsored insurance and non-group coverage posted only modest gains.

The takeaway is straightforward: other forms of coverage are not fully absorbing those losing Medicaid eligibility. Instead, a meaningful share of individuals are becoming uninsured.

Why it matters: This is more than a payer mix story. Rising uninsured rates could increase uncompensated care pressures on hospitals, particularly safety-net providers and pediatric health systems. Providers with significant Medicaid exposure may see higher bad debt and delayed care utilization, while insurers operating in ACA marketplaces could benefit if more individuals transition to exchange plans.

For investors and operators, the data suggests that the Medicaid redetermination cycle is evolving from a temporary administrative event into a structural headwind for healthcare access and provider economics.

Bottom line: The pandemic-era expansion of coverage is beginning to unwind, and the financial consequences are likely to be felt first by providers serving the most vulnerable populations. (More)

DEAL OF THE WEEK

Vertex Bets $10B on Endocrinology with Crinetics Acquisition

After several quarters of cautious dealmaking, large-cap biotech M&A is back. Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, marking one of the largest healthcare transactions of the year and signaling renewed confidence in late-stage, commercial-ready biotech assets.

The acquisition gives Vertex immediate access to Palsonify, an FDA-approved treatment for acromegaly, alongside a pipeline of endocrine therapies with blockbuster potential. More importantly, the deal expands Vertex beyond its historical dependence on cystic fibrosis, providing a new long-term growth platform in endocrinology—a therapeutic area with significant unmet need and attractive commercial dynamics.

For investors, the transaction sends a broader message than the acquisition itself. Large pharmaceutical companies are once again willing to pay meaningful premiums for companies with validated science, commercial infrastructure, and near-term revenue visibility. With patent expirations looming across the industry and balance sheets still well capitalized, this deal could mark the beginning of a new cycle of strategic biotech consolidation.

Why it matters: The M&A window for high-quality biotech assets may be reopening faster than many expected. Read more.

DEAL TRACKER

MatrixCare (ResMed) → Frazier Healthcare Partners | $490M
Healthcare IT divestiture — ResMed is selling its MatrixCare home-health and senior-care software business (~$220M revenue, ~$55M adj. EBITDA) to PE firm Frazier for $490M cash. ResMed sharpens focus on sleep, breathing and home-based care; proceeds earmarked for buybacks. Read more.

MeiraGTx | $400M financing from Oberland Capital
Non-dilutive royalty financing — MeiraGTx secured up to $375M in senior secured royalty notes + $25M equity from Oberland Capital to fund commercialization of two late-stage gene therapies (bota-vec for XLRP and AAV2-hAQP1 for radiation-induced xerostomia). Initial tranche: $135M. Oberland gets low single-digit capped royalties on future net sales. Read more.

Myricx Bio → Novartis | up to $1.5B
Pharma M&A — Novartis acquires UK-based private biotech Myricx Bio for $1.1B upfront + up to $400M in milestones. Deal marks Novartis' entry into next-gen ADC payloads via Myricx's NMTi platform, targeting HER2 and B7-H3 solid tumors. Expected to close H2 2026. Read more.

Vega Therapeutics (Star Therapeutics) → Incyte | $1.25B upfront / up to $2B
Pharma M&A — Incyte closed its acquisition of Vega Therapeutics, gaining VGA039, a Phase 3 monoclonal antibody for von Willebrand disease (VWD), the most common inherited bleeding disorder. Deal is Incyte's largest-ever M&A move, ahead of its Jakafi patent cliff in 2028. Read more.

REGIONAL FOCUS

Fertility Goes Global

For decades, fertility care was viewed as a specialized, high-cost service concentrated in a handful of developed markets. Today, it has become one of healthcare's fastest-scaling investment categories.

The global fertility procedures and ancillary services market is projected to expand from $12.9 billion in 2024 to $19.0 billion by 2029. While the US & Canada remain the largest regional market and Europe continues to be a key growth engine, the rest of the world is steadily increasing its footprint, fueled by rising infertility rates, delayed parenthood, improving access to care, and broader reimbursement support.

What makes fertility particularly noteworthy is that it has already crossed a milestone many healthcare verticals have yet to achieve: institutional scale. Private equity has consolidated IVF clinics into regional and global platforms, while advances in technology and supportive regulation have transformed a once-fragmented niche into a predictable, investable healthcare market.

Why it matters: Fertility is becoming the blueprint for the broader women's health sector. It demonstrates that when clinical innovation, reimbursement, and demographic demand align, a specialized medical service can evolve into a global, multibillion-dollar industry—offering a roadmap for the next generation of women's health investments. Read more.

INTERESTING ARTICLES